Herbert J, Roser B
Immunology Department, Institute of Animal Physiology and Genetics Research, Babraham, Cambridge.
Transplantation. 1988 Aug;46(2 Suppl):128S-134S. doi: 10.1097/00007890-198808001-00024.
Treatment of normal rats with certain monoclonal anti-CD4 antibodies, beginning on the day of grafting, prevents heart graft rejection across a full MHC-haplotype mismatch. Adequate doses of antibody MRC OX-35, which is very potent in vivo, led to the induction of authentic specific tolerance of the transplants. In the very stringent grafting test of transplantation of DA skin to high-responder LOU recipients, adjunctive therapy with cyclosporine, in addition to the anti-CD4 antibodies, is required to induce tolerance. Since tolerance persists indefinitely after a 30-day course of treatment and appears to involve T cell-mediated suppression, this form of treatment is of potential clinical interest.
从移植当天开始,用某些单克隆抗CD4抗体治疗正常大鼠,可防止完全MHC单倍型不匹配的心脏移植排斥反应。足够剂量的抗体MRC OX-35在体内非常有效,可诱导移植的真正特异性耐受。在将DA皮肤移植到高反应性LOU受体的非常严格的移植试验中,除抗CD4抗体外,还需要用环孢素进行辅助治疗以诱导耐受。由于在30天的疗程后耐受会无限期持续,且似乎涉及T细胞介导的抑制作用,这种治疗形式具有潜在的临床意义。